For example, a recent phase 2 study of the macrophage activation inhibitor NP001 [120] only enrolled ALS patients with plasma C-reactive protein (CRP) concentration greater than or equal to 0.113 mg/dL (NCT02794857) [96]. Here, CRP is linked to amyotrophic lateral sclerosis.